Actelion Ltd (ATLN.VX)
61.50CHF
31 Jul 2013
CHF0.50 (+0.82%)
CHF61.00
CHF60.75
CHF61.90
CHF60.75
479,923
418,965
CHF62.30
CHF42.85
About
Overall
| Beta: | 0.59 |
| Market Cap (Mil.): | CHF7,396.97 |
| Shares Outstanding (Mil.): | 120.28 |
| Dividend: | 1.00 |
| Yield (%): | 1.63 |
Financials
| ATLN.VX | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 21.75 | 47.13 | 37.76 |
| EPS (TTM): | 2.83 | -- | -- |
| ROI: | 16.61 | -2.58 | 18.76 |
| ROE: | 22.22 | -2.66 | 19.59 |
UPDATE 1-Actelion buys U.S.-based specialty drugmaker Ceptaris
* Ceptaris drug Valchlor set to be addressed by FDA in Aug
Actelion buys U.S.-based firm with cancer drug in development
ZURICH - Actelion said it will acquire Ceptaris, a privately held U.S.-based specialty pharmaceutical company developing a topical drug, Valchlor, to treat a form of cancer.
Actelion raises profit forecast as cost cuts kick in
ZURICH - Actelion , the Swiss drugmaker which relies on sales of its treatment for a rare lung disease, raised its full-year profit forecast on Thursday on cost-savings and better-than-expected sales of its mainstay product.
UPDATE 2-Actelion raises profit forecast as cost cuts kick in
* Shares rise 1 pct, outperform flat sector (Adds CFO comment, shares, details on ponesimod)
BRIEF-Shares in Actelion up 2 pct after raises forecast
ZURICH, July 18 - Actelion Ltd : * Shares in Actelion rise 2 percent after raises profit growth forecast for
Actelion CFO sees room for upside to 2014, 2015 guidance
ZURICH, July 18 - Actelion could upgrade its earnings guidance for 2014 and 2015 if sales of its new heart and lung drug are better than expected, the company's Chief Financial Officer said on Thursday.
CORRECTED-Actelion raises full-year guidance
ZURICH, July 18 - Actelion, Europe's largest biotech company lifted its full-year guidance on Thursday and now expects to return to growth in 2013 boosted by strong sales of its mainstay product and benefits from its cost-savings programme.
UPDATE 1-Actelion gets go-ahead to continue new drug trial
* Selexipag is new drug for pulmonary arterial hypertension
Actelion gets go-ahead to continue new drug trial
ZURICH, May 8 - Actelion should continue a late-stage study into a new heart and lung drug, independent monitors have recommmended, with final results now expected by mid-2014, giving the biotech firm hope it has a further product in its pipeline.
Actelion shareholders reject biotech firm's pay plans
BASEL - Actelion shareholders rejected a $5.6 million pay award for the biotechnology company's chief executive Jean-Paul Clozel on Thursday, making it the second Swiss company in as many weeks to have its pay plans voted down by investors.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$483.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

